Below you'll find a list of all posts that have been tagged as “Kyowa Hakko Kirin”
Tokyo, Japan, January 6th , 2020 — Kyowa Kirin Co., Ltd. (TSE: 4151 President and CEO: Masashi Miyamoto, “Kyowa Kirin”) today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinson’s disease (PD) experiencing “OFF” time, has been validated by the European Medicines Agency (EMA) and is now under …
First Approved Treatment for XLH in Canada that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease.
Borders-based specialty pharmaceutical company, Kyowa Kirin International plc (KKI), hosted Dr. Nobuo Hanai, President and Chief Executive Officer of KKI’s parent company, Kyowa Hakko Kirin Co. Ltd., at the company’s head office in Galashiels this week.
Spreng Thomson: Intelligent Creative Communications
Spreng Thomson is committed to Fair Work, by ensuring that our people have an effective voice, by investing in their development and by not using zero hours contracts.
+44(0)141 548 5191
[email protected]
The Herald Building,
155 Albion Street,
Glasgow G1 1RU, UK
© 2023 Spreng Thomson Limited.
Registered in Scotland No. 173454
